RESEARKA

The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

Citation Support

• source_1 Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
• source_2 Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
• source_3 Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
• source_4 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
• source_5 Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial